Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder

Long-acting buprenorphine formulations have been recently marketed for the Opioid Agonist Treatment (OAT) of opioid use disorder (OUD) associated with medical, social, and psychological support. Their duration of action ranges from one week up to 6 months. The non-medical use of opioids is increasin...

Descripción completa

Detalles Bibliográficos
Autores principales: Maremmani, Icro, Dematteis, Maurice, Gorzelanczyk, Edward J., Mugelli, Alessandro, Walcher, Stephan, Torrens, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488107/
https://www.ncbi.nlm.nih.gov/pubmed/37685642
http://dx.doi.org/10.3390/jcm12175575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488107/
https://www.ncbi.nlm.nih.gov/pubmed/37685642
http://dx.doi.org/10.3390/jcm12175575

Ejemplares similares